Published in Drug Week, May 29th, 2009
"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.
Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.